Loading...
Header Logo
Keywords
Last Name
Institution

POWEL H BROWN

TitleProfessor
InstitutionMD Anderson
DepartmentClinical Cancer Prevention
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Brown P. Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved. Oncologist. 2016 Jan; 21(1):4-6. PMID: 26675741.
      View in: PubMed
    2. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. 2015 Sep-Oct; 65(5):345-83. PMID: 26284997.
      View in: PubMed
    3. Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest. 2015 Jul 01; 125(7):2707-20. PMID: 26075823.
      View in: PubMed
    4. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih IeM, Uray IP, Wu X, Brown PH, Shen X, Mills GB, Peng G. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 2015 Jul; 5(7):752-67. PMID: 26069190.
      View in: PubMed
    5. Haricharan S, Brown P. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):E3216-25. PMID: 26063617.
      View in: PubMed
    6. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14. PMID: 25605252.
      View in: PubMed
    7. Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014 Dec; 15(13):e625-e634. PMID: 25456381.
      View in: PubMed
    8. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A. Prevention and early detection of prostate cancer. Lancet Oncol. 2014 Oct; 15(11):e484-92. PMID: 25281467.
      View in: PubMed
    9. Rechoum Y, Rovito D, Iacopetta D, Barone I, Andò S, Weigel NL, O'Malley BW, Brown PH, Fuqua SA. AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85. PMID: 25178514.
      View in: PubMed
    10. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep; 7(9):886-95. PMID: 24961880.
      View in: PubMed
    11. Haricharan S, Bainbridge MN, Scheet P, Brown PH. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat. 2014 Jul; 146(1):211-20. PMID: 24839032.
      View in: PubMed
    12. Brown P. Prevention: targeted therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol. 2014 Mar; 11(3):127-8. PMID: 24535168.
      View in: PubMed
    13. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013 Sep 23; 3:250. PMID: 24069582.
      View in: PubMed
    14. Poage GM, Hartman ZC, Brown PH. Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy. Cell Cycle. 2013 Sep 01; 12(17):2705-6. PMID: 23966168.
      View in: PubMed
    15. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG, Wade JL, Lippman SM. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10; 31(23):2942-62. PMID: 23835710.
      View in: PubMed
    16. Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJ. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013 Jul; 6(7):646-55. PMID: 23682075.
      View in: PubMed
    17. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013 Jun 01; 73(11):3470-80. PMID: 23633491.
      View in: PubMed
    18. Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, Bissonnette RP, Brown PH. The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. Cancer Prev Res (Phila). 2012 Oct; 5(10):1195-202. PMID: 22926341.
      View in: PubMed
    19. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54. PMID: 22827973.
      View in: PubMed
    20. Mohebati A, Knutson A, Zhou XK, Smith JJ, Brown PH, Dannenberg AJ, Szabo E. A web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokers. Contemp Clin Trials. 2012 Sep; 33(5):942-8. PMID: 22771576.
      View in: PubMed
    21. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor ß in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012 Sep; 9(9):530-8. PMID: 22710573.
      View in: PubMed
    22. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother. 2012 Feb; 13(3):325-31. PMID: 22242911.
      View in: PubMed
    23. Wang C, Uray IP, Mazumdar A, Mayer JA, Brown PH. SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE). Breast Cancer Res Treat. 2012 Jul; 134(1):101-15. PMID: 22212555.
      View in: PubMed
    24. Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. A SNP in steroid receptor coactivator-1 disrupts a GSK3ß phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol. 2012 Feb; 26(2):220-7. PMID: 22174377.
      View in: PubMed
    25. Uray IP, Rodenberg JM, Bissonnette RP, Brown PH, Mancini MA. Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor ?-dependent mechanism. Mol Pharmacol. 2012 Feb; 81(2):228-38. PMID: 22053058.
      View in: PubMed
    26. Wang C, Mayer JA, Mazumdar A, Brown PH. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat. 2012 Jun; 133(2):487-500. PMID: 21947652.
      View in: PubMed
    27. Dearth RK, Kuiatse I, Wang YF, Liao L, Hilsenbeck SG, Brown PH, Xu J, Lee AV. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377. PMID: 21867536.
      View in: PubMed
    28. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol. 2011 Sep; 25(9):1527-38. PMID: 21835891.
      View in: PubMed
    29. Howe LR, Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila). 2011 Aug; 4(8):1149-57. PMID: 21816844.
      View in: PubMed
    30. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011 Jul 08; 8(1):11. PMID: 21906370.
      View in: PubMed
    31. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73. PMID: 21541704.
      View in: PubMed
    32. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503. PMID: 21441069.
      View in: PubMed
    33. Zhang G, Brewster A, Guan B, Fan Z, Brown PH, Xu XC. Tumor-suppressor activity of RRIG1 in breast cancer. BMC Cancer. 2011 Jan 25; 11:32. PMID: 21266059.
      View in: PubMed
    34. Uray IP, Brown PH. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res. 2011; 188:147-62. PMID: 21253797.
      View in: PubMed
    35. Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8. PMID: 20921021.
      View in: PubMed
    36. Li Y, Shen Q, Kim HT, Bissonnette RP, Lamph WW, Yan B, Brown PH. The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast Cancer Res Treat. 2011 Aug; 128(3):667-77. PMID: 20821348.
      View in: PubMed
    37. Johnson KA, Brown PH. Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol. 2010 Aug; 37(4):345-58. PMID: 20816505.
      View in: PubMed
    38. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40. PMID: 20569503.
      View in: PubMed
    39. Hortobagyi GN, Brown PH. Two good choices to prevent breast cancer: great taste, less filling. Cancer Prev Res (Phila). 2010 Jun; 3(6):681-5. PMID: 20522797.
      View in: PubMed
    40. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61. PMID: 19920204.
      View in: PubMed
    41. Brown PH, Viner JL, Brewster A, Heckman CJ, Hursting S, Johnson K, Mao JT. Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila). 2009 Nov; 2(11):995-8. PMID: 19892666.
      View in: PubMed
    42. Rodenberg JM, Brown PH. A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin. Cancer Prev Res (Phila). 2009 Nov; 2(11):915-8. PMID: 19861544.
      View in: PubMed
    43. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40. PMID: 19808870.
      View in: PubMed
    44. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 01; 27(19):3235-58. PMID: 19470930.
      View in: PubMed
    45. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009 May; 10(5):501-7. PMID: 19410194.
      View in: PubMed
    46. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14. PMID: 19241157.
      View in: PubMed
    47. Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, Brown PH. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74. PMID: 19174577.
      View in: PubMed
    48. Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Hill J, Bissonnette RP, Brown PH, Medina D, Aldaz CM. Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer Prev Res (Phila). 2009 Feb; 2(2):175-84. PMID: 19174580.
      View in: PubMed
    49. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13. PMID: 19141783.
      View in: PubMed
    50. Li Y, Brown PH. Prevention of ER-negative breast cancer. Recent Results Cancer Res. 2009; 181:121-34. PMID: 19213564.
      View in: PubMed
    51. Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS. American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol. 2009 Feb 20; 27(6):986-93. PMID: 19075281.
      View in: PubMed
    52. Speers C, Brown P. Breast cancer prevention using calcium and vitamin D: a bright future? J Natl Cancer Inst. 2008 Nov 19; 100(22):1562-4. PMID: 19001596.
      View in: PubMed
    53. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5. PMID: 18990728.
      View in: PubMed
    54. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5. PMID: 19138984.
      View in: PubMed
    55. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem. 2009 Jan 02; 284(1):345-53. PMID: 18957410.
      View in: PubMed
    56. Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Zhang Y, Hill J, Bissonnette RP, Medina D, Brown PH, Aldaz CM. Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. BMC Med Genomics. 2008 Sep 11; 1:40. PMID: 18786257.
      View in: PubMed
    57. Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D. The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila). 2008 Aug; 1(3):161-6. PMID: 19138951.
      View in: PubMed
    58. Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LR. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila). 2008 Aug; 1(3):208-14. PMID: 19138958.
      View in: PubMed
    59. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55. PMID: 19138935.
      View in: PubMed
    60. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer. 2008 Apr 22; 98(8):1380-8. PMID: 18362934.
      View in: PubMed
    61. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31. PMID: 17947490.
      View in: PubMed
    62. Hoque A, Parnes HL, Stefanek ME, Heymach JV, Brown PH, Lippman SM. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res. 2007 Oct 01; 67(19):8989-93. PMID: 17895292.
      View in: PubMed
    63. Brown PH. Chemoprevention clinical trials: it is time to turn success into progress. Cancer Epidemiol Biomarkers Prev. 2007 Aug; 16(8):1531-2. PMID: 17684123.
      View in: PubMed
    64. DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PH. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol. 2007 Oct 15; 277(1-2):13-25. PMID: 17825481.
      View in: PubMed
    65. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2008 Jan 10; 27(3):366-77. PMID: 17637753.
      View in: PubMed
    66. Li Y, Brown PH. Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev. 2007 Jun; 16(3):203-15. PMID: 17415091.
      View in: PubMed
    67. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76. PMID: 17493263.
      View in: PubMed
    68. Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 2007; 9(1):R12. PMID: 17257424.
      View in: PubMed
    69. Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18. PMID: 17178900.
      View in: PubMed
    70. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem. 2007 Feb 09; 282(6):3507-19. PMID: 17158870.
      View in: PubMed
    71. Uray IP, Brown PH. Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs. 2006 Dec; 15(12):1583-600. PMID: 17107283.
      View in: PubMed
    72. Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TC. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol. 2007 Feb 15; 73(4):481-90. PMID: 17126817.
      View in: PubMed
    73. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5902-9. PMID: 17020999.
      View in: PubMed
    74. Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 2006 May 15; 66(10):5304-13. PMID: 16707456.
      View in: PubMed
    75. Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J. 2006 May 01; 395(3):653-62. PMID: 16417524.
      View in: PubMed
    76. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006 Jul 15; 295(2):589-603. PMID: 16678816.
      View in: PubMed
    77. Seo HS, DeNardo DG, Jacquot Y, Laïos I, Vidal DS, Zambrana CR, Leclercq G, Brown PH. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat. 2006 Sep; 99(2):121-34. PMID: 16541309.
      View in: PubMed
    78. Jang KS, Han HX, Paik SS, Brown PH, Kong G. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 2006 Dec 08; 244(2):203-10. PMID: 16469432.
      View in: PubMed
    79. Wu K, DuPré E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat. 2006 Mar; 96(2):147-57. PMID: 16273314.
      View in: PubMed
    80. Lu C, Shen Q, DuPré E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24. PMID: 16027729.
      View in: PubMed
    81. Shen Q, Brown PH. Transgenic mouse models for the prevention of breast cancer. Mutat Res. 2005 Aug 25; 576(1-2):93-110. PMID: 15888345.
      View in: PubMed
    82. Brown PH, Rashid A. Cancer prevention: the importance of accurate risk assessment. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1357-8. PMID: 15941935.
      View in: PubMed
    83. Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005 Apr 15; 65(8):3462-9. PMID: 15833882.
      View in: PubMed
    84. Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res. 2005 Apr 15; 65(8):3493-6. PMID: 15833886.
      View in: PubMed
    85. Kalidas M, Brown P. Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer. 2005 Apr; 6(1):27-37. PMID: 15899070.
      View in: PubMed
    86. Brown P. Risk assessment: controversies and management of moderate- to high-risk individuals. Breast J. 2005 Mar-Apr; 11 Suppl 1:S11-9. PMID: 15725110.
      View in: PubMed
    87. Kalidas M, Hilsenbeck S, Brown P. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3. PMID: 15572750.
      View in: PubMed
    88. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78. PMID: 15514030.
      View in: PubMed
    89. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene. 2004 Oct 28; 23(50):8238-46. PMID: 15378019.
      View in: PubMed
    90. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6(6):240-5. PMID: 15535853.
      View in: PubMed
    91. Campiglio M, Normanno N, Ménard S. Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2004 May 05; 96(9):715; author reply 715-6. PMID: 15126613.
      View in: PubMed
    92. Kramer R, Brown P. Should tamoxifen be used in breast cancer prevention? Drug Saf. 2004; 27(13):979-89. PMID: 15471505.
      View in: PubMed
    93. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33. PMID: 14679152.
      View in: PubMed
    94. Schiff R, Chamness GC, Brown PH. Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31. PMID: 12927029.
      View in: PubMed
    95. Wu K, Brown P. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst. 2003 Jun 04; 95(11):766-7. PMID: 12783921.
      View in: PubMed
    96. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia. 2003 Jan; 8(1):45-73. PMID: 14587863.
      View in: PubMed
    97. Ip C, Brown P. Prevention of breast cancer--present reality and future promise. J Mammary Gland Biol Neoplasia. 2003 Jan; 8(1):1-3. PMID: 14587859.
      View in: PubMed
    98. Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, Green JE. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res. 2002 Dec; 11(6):617-33. PMID: 12509137.
      View in: PubMed
    99. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80. PMID: 12438218.
      View in: PubMed
    100. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9. PMID: 12400010.
      View in: PubMed
    101. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW. The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem. 2002 Jul 12; 277(28):25313-22. PMID: 12000762.
      View in: PubMed
    102. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74. PMID: 12010861.
      View in: PubMed
    103. You H, Yu W, Munoz-Medellin D, Brown PH, Sanders BG, Kline K. Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog. 2002 Apr; 33(4):228-36. PMID: 11933076.
      View in: PubMed
    104. Yang L, Ostrowski J, Reczek P, Brown P. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene. 2001 Nov 29; 20(55):8025-35. PMID: 11753686.
      View in: PubMed
    105. Ludes-Meyers JH, Liu Y, Muñoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80. PMID: 11420689.
      View in: PubMed
    106. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem. 2001 Jul 27; 276(30):27907-12. PMID: 11353774.
      View in: PubMed
    107. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34. PMID: 11106684.
      View in: PubMed
    108. Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704. PMID: 10999763.
      View in: PubMed
    109. Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast Cancer Res Treat. 2000 Jul; 62(1):1-17. PMID: 10989982.
      View in: PubMed
    110. Lippman SM, Brown PH. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst. 1999 Nov 03; 91(21):1809-19. PMID: 10547388.
      View in: PubMed
    111. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70. PMID: 10557095.
      View in: PubMed
    112. Yang LM, Tin-U C, Wu K, Brown P. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia. 1999 Oct; 4(4):377-88. PMID: 10705921.
      View in: PubMed
    113. Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH. Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat. 1999 Aug; 56(3):277-91. PMID: 10573118.
      View in: PubMed
    114. Yu W, Simmons-Menchaca M, You H, Brown P, Birrer MJ, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog. 1998 Aug; 22(4):247-57. PMID: 9726817.
      View in: PubMed
    115. Osborne CK, Elledge RM, Brown PH, Hilsenbeck SG. BRCA1 in clinical breast cancer. Breast Dis. 1998 Apr; 10(1-2):77-88. PMID: 15687551.
      View in: PubMed
    116. Yang L, Kim HT, Munoz-Medellin D, Reddy P, Brown PH. Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res. 1997 Oct 15; 57(20):4652-61. PMID: 9377582.
      View in: PubMed
    117. Smith LM, Birrer MJ, Stampfer MR, Brown PH. Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997 Jul 15; 57(14):3046-54. PMID: 9230221.
      View in: PubMed
    118. Zhao B, Yu W, Qian M, Simmons-Menchaca M, Brown P, Birrer MJ, Sanders BG, Kline K. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog. 1997 Jul; 19(3):180-90. PMID: 9254885.
      View in: PubMed
    119. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ. 1996 Aug; 7(8):1013-21. PMID: 8853897.
      View in: PubMed
    120. Kim S, Brown PH, Birrer MJ. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Oncogene. 1996 Mar 07; 12(5):1043-53. PMID: 8649795.
      View in: PubMed
    121. Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar; 15(3):215-26. PMID: 8597534.
      View in: PubMed
    122. Battey JF, Brown PH, Gritz ER, Hong WK, Johnson BE, Karp DD, Mulshine JL, Shaw GL, Shopland DR, Sunday ME, et al. Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. Lung Cancer. 1995 Mar; 12(1-2):91-103. PMID: 7600036.
      View in: PubMed
    123. Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 1994 Mar; 9(3):791-9. PMID: 8108121.
      View in: PubMed
    124. Kurie JM, Brown P, Salk E, Scheinberg D, Birrer M, Deutsch P, Dmitrovsky E. Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. Differentiation. 1993 Sep; 54(2):115-22. PMID: 8243888.
      View in: PubMed
    125. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 1993 Apr; 8(4):877-86. PMID: 8455942.
      View in: PubMed
    126. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S. PMID: 8380133.
      View in: PubMed
    127. Birrer MJ, Brown PH. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res. 1992 May 01; 52(9 Suppl):2658s-2664s. PMID: 1562996.
      View in: PubMed
    128. Birrer MJ, Alani R, Cuttitta F, Preis LH, Sabich AL, Sanders DA, Siegfried JM, Szabo E, Brown PH. Early events in the neoplastic transformation of respiratory epithelium. J Natl Cancer Inst Monogr. 1992; (13):31-7. PMID: 1389694.
      View in: PubMed
    129. Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJ, et al. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem Suppl. 1992; 16G:183-6. PMID: 1469899.
      View in: PubMed
    130. Alani R, Brown P, Binétruy B, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer MJ. The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol. 1991 Dec; 11(12):6286-95. PMID: 1944289.
      View in: PubMed
    131. Szabo E, Preis LH, Brown PH, Birrer MJ. The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. Cell Growth Differ. 1991 Oct; 2(10):475-82. PMID: 1751404.
      View in: PubMed
    132. Ponzio NM, Brown PH, Thorbecke GJ. Host-tumor interactions in the SJL lymphoma model. Int Rev Immunol. 1986 Jul; 1(3-4):273-301. PMID: 3334050.
      View in: PubMed
    133. Brown PH, Coico RF, Thorbecke GJ. Proliferative responses of T cells from SJL----F1 and F1----SJL bone marrow chimeras to SJL lymphoma cells. Cell Immunol. 1986 Mar; 98(1):18-27. PMID: 3527449.
      View in: PubMed
    134. Brown PH, Thorbecke GJ. Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T cells. J Immunol. 1985 Nov; 135(5):3572-80. PMID: 3900211.
      View in: PubMed
    135. DeKruyff RH, Brown PH, Thorbecke GJ, Ponzio NM. Characterization of SJL T cell clones responsive to syngeneic lymphoma (RCS): RCS-specific clones are stimulated by activated B cells. J Immunol. 1985 Nov; 135(5):3581-6. PMID: 2413126.
      View in: PubMed
    136. Brown PH, Mathis D, Cone RE, Jones PP, Ponzio NM, Thorbecke GJ. Properties of reticulum cell sarcomas in SJL/J mice. VIII. Prominent role of RCS cell I-A antigens in the stimulation of syngeneic T cells. Immunogenetics. 1983; 18(4):399-413. PMID: 6226603.
      View in: PubMed
    137. Phase ib randomized, Double-blinded, Placebo- Controlled, Dose escalation study of polyphenon e in patients with barrett's esophagus. Cancer Prevention Research. 8:1131-1137.
    138. 9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu-transgenic mice. Breast Cancer Research and Treatment. 69:226.
    139. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research. 21:1688-1698.
    140. Development of SJL T cell clones responsive to syngeneic lymphoma (RCS) and activated B cells. Federation Proceedings. 44:3237.
    141. Blockade of AP-1 potentiates endocrine therapy and overcomes resistance. Molecular Cancer Research. 14:470-481.
    142. Long-term effects of inhaled budesonide on screening-detected lung nodules. Annals of Oncology. 26:1025-1030.
    143. Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment. 141:375-384.
    144. Retinoids and rexinoids in cancer prevention. Seminars in Oncology. 43:49-64.
    145. Federation Proceedings. 43.
    146. American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Oncology Practice. 5:196-199.
    147. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    148. Advances in targeted therapy for the prevention of breast cancer. Breast Diseases. 24:309-314.
    149. Identification of proteins associated with the AP-1 transcription factor that are critical for breast cancer growth. Breast Cancer Research and Treatment. 69:234.
    150. Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer. Clinical Cancer Research. 22:5864-5875.
    151. Oncologist. 21:4-6.
    152. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. Journal of Cellular Biochemistry. 50:183-186.
    153. Overexpression of cJun in breast cancer cells inhibits growth and induces cell death. Breast Cancer Research and Treatment. 69:273.
    154. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    155. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II). Breast Diseases. 25:214-216.
    156. Advances in preventive therapy for estrogen-receptor-negative breast cancer. Current Breast Cancer Reports. 6:96-109.
    157. Cancer Prevention, Screening, and Early Detection. 322-359.
    158. Effects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics.
    159. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Breast Diseases. 16:73-74.
    160. Strategies of hormonal prevention. 195-229.
    161. Chemoprevention.
    162. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 7:13106-13121.
    163. AP-1 blockade in vivo suppresses development of mammary tumor im MMTV- erbB2 mice. Cancer Epidemiology, Biomarkers and Prevention. 14.
    164. Animal models for breast cancer prevention research. 497-526.
    165. RXR-selective retinoids function independently of RAR and PPARγ to inhibit breast cell growth. Breast Cancer Research and Treatment. 69:274.
    166. Targeted therapy for breast cancer prevention. Frontiers in Oncology. 3 SEP.
    167. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Research. 76:1942-1953.
    168. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment. 1-14.
    BROWN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description